Shengmai Injection Orchestrates Lipid Metabolism and Anti-Tumor Immunity to Suppress Colorectal Cancer: A Multi-Omics and Preclinical Study

The malignant progression of colorectal cancer (CRC) is driven by alterations in lipid metabolism and dysregulation in the immune microenvironment, which serve as key biological hallmarks. The clinical predicaments of unfavorable prognosis and limited efficacy of immunotherapy remain substantial challenges in the comprehensive management of CRC. Shengmai Injection (SMI), a traditional Chinese medicine formulation, has shown potential anti-cancer effects. This study aims to explore its anti-tumor properties in CRC, focusing on its impact on lipid metabolism and the tumor immune microenvironment, and its potential synergy with immune checkpoint blockade (ICB) therapy. To assess the anti-tumor potential of SMI, experiments were conducted in allograft mouse models, CRC cell lines, and patient-derived organoids. Lipidomic analysis was conducted to evaluate alterations in lipid metabolism. The infiltration of CD8 + T cells and the expression of PD-L1 were examined via multiplex immunohistochemistry (mIHC) and flow cytometry. The synergistic effect of SMI combined with PD-1 monoclonal antibody was also tested. RNA-seq and western blotting were employed to investigate the underlying molecular mechanisms. SMI played a significant role in suppressing tumor growth in vitro and in vivo by curbing cell proliferation and inducing apoptosis. Lipidomic profiling revealed that SMI disrupted lipid metabolism, particularly by suppressing lipid biosynthesis and reducing intracellular lipid accumulation in tumor cells. mIHC and flow cytometry assays confirmed that SMI dose-dependently downregulated PD-L1 expression in tumor cells, while simultaneously promoting CD8 + T cell infiltration and enhancing their cytotoxic functions. Of particular significance, the combined application of SMI with PD-1 monoclonal antibody demonstrated remarkable synergistic anti-tumor effects, with therapeutic efficacy significantly superior to that observed in monotherapy groups. Integrated analyses of network pharmacology and RNA-seq, combined with molecular biological validation, demonstrated that SMI inhibited the Akt-mTOR signaling pathway to block lipid synthesis in tumor cells, while suppressing the JAK1–STAT3 pathway to downregulate PD-L1 protein expression, thereby alleviating immunosuppression and activating anti-tumor immune responses mediated by CD8 + T cells. SMI exhibits significant anti-tumor activity in CRC by orchestrating lipid metabolism and enhancing immune responses. The combined application of SMI with PD-1 monoclonal antibody demonstrated remarkable synergistic anti-tumor effects, providing novel theoretical foundations and clinical translational insights for the combination of traditional Chinese medicine preparations with ICB therapy, with promising potential to open new avenues for precision adjuvant therapy of CRC.

Authors

Institutions

Publication Details

Journal
Biological Procedures Online
Published
2026-11-21
DOI
https://doi.org/10.1186/s12575-026-00369-7
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Shengmai Injection Orchestrates Lipid Metabolism and Anti-Tumor Immunity to Suppress Colorectal Cancer: A Multi-Omics and Preclinical Study

Zhihai Mao, Jing Ping Sun, Xiao Bing Xi, Wei Yan et al.
Biological Procedures Online
Cancer Immunotherapy and Biomarkers
article

Shengmai Injection Orchestrates Lipid Metabolism and Anti-Tumor Immunity to Suppress Colorectal Cancer: A Multi-Omics and Preclinical Study

Zhihai Mao, Jing Ping Sun, Xiao Bing Xi, Wei Yan, Jing Sun, Yi Lu, Minhua Zheng, Yichen Zhao, Sen Zhang, Joshua Lin, Huang Zheng, Yi Yang
article en

Abstract

The malignant progression of colorectal cancer (CRC) is driven by alterations in lipid metabolism and dysregulation in the immune microenvironment, which serve as key biological hallmarks. The clinical predicaments of unfavorable prognosis and limited efficacy of immunotherapy remain substantial challenges in the comprehensive management of CRC. Shengmai Injection (SMI), a traditional Chinese medicine formulation, has shown potential anti-cancer effects. This study aims to explore its anti-tumor properties in CRC, focusing on its impact on lipid metabolism and the tumor immune microenvironment, and its potential synergy with immune checkpoint blockade (ICB) therapy. To assess the anti-tumor potential of SMI, experiments were conducted in allograft mouse models, CRC cell lines, and patient-derived organoids. Lipidomic analysis was conducted to evaluate alterations in lipid metabolism. The infiltration of CD8 + T cells and the expression of PD-L1 were examined via multiplex immunohistochemistry (mIHC) and flow cytometry. The synergistic effect of SMI combined with PD-1 monoclonal antibody was also tested. RNA-seq and western blotting were employed to investigate the underlying molecular mechanisms. SMI played a significant role in suppressing tumor growth in vitro and in vivo by curbing cell proliferation and inducing apoptosis. Lipidomic profiling revealed that SMI disrupted lipid metabolism, particularly by suppressing lipid biosynthesis and reducing intracellular lipid accumulation in tumor cells. mIHC and flow cytometry assays confirmed that SMI dose-dependently downregulated PD-L1 expression in tumor cells, while simultaneously promoting CD8 + T cell infiltration and enhancing their cytotoxic functions. Of particular significance, the combined application of SMI with PD-1 monoclonal antibody demonstrated remarkable synergistic anti-tumor effects, with therapeutic efficacy significantly superior to that observed in monotherapy groups. Integrated analyses of network pharmacology and RNA-seq, combined with molecular biological validation, demonstrated that SMI inhibited the Akt-mTOR signaling pathway to block lipid synthesis in tumor cells, while suppressing the JAK1–STAT3 pathway to downregulate PD-L1 protein expression, thereby alleviating immunosuppression and activating anti-tumor immune responses mediated by CD8 + T cells. SMI exhibits significant anti-tumor activity in CRC by orchestrating lipid metabolism and enhancing immune responses. The combined application of SMI with PD-1 monoclonal antibody demonstrated remarkable synergistic anti-tumor effects, providing novel theoretical foundations and clinical translational insights for the combination of traditional Chinese medicine preparations with ICB therapy, with promising potential to open new avenues for precision adjuvant therapy of CRC.

Biological Procedures Online
Shanghai Jiao Tong University (CN), Ruijin Hospital (CN)
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon